The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice

Vaccine

Volumn 15, Issue 16, 1997, Pages 1710-1715

  Cataldo, Darci M ^a   Van Nest, Gary ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Adjuvant; Influenza; Protection

Indexed keywords

ADJUVANT; INFLUENZA VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROVOCATION TEST; SURVIVAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; INFLUENZA A VIRUS; INFLUENZA VACCINES; LUNG; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; POLYSORBATES; SQUALENE;

EID: 0030880922     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00115-1     Document Type: Article

References (35)

1. Dindinaud, G., Potiron, G., Agius, G., Ferron, V., Burucoa, C., Bourgoin, A., Grollier, G., Peletier, M.P., Perivier, E. and Castets, M. Influenza epidemic among a community of elderly people in spite of vaccination. European Journal of Epidemiology 1993, 9, 667-670.
2. Gross, P.A., Hermogenes, A.W., Sacks, H.S., Lau, J. and Levandowski, R.A. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Annals of International Medicine 1995, 123, 518-527.
3. Potter, C.W. Inactivated influenza virus vaccines. In Basic and Applied Influenza Research (Ed Beare, A.S.). CRC Press, Boca Raton, FL, 1982, pp. 119-158.
4. Sugaya, N., Nerome, K., Ishida, M., MatsuMoto, M., MitaMura, K. and Nirasawa, M. Efficacy of inactivated vaccine in preventing antigenically drifted influenza type a and well-matched type b. JAMA 1994, 272, 1122-1126.
5. Edwards, K.M., Dupont, W.D., Westrich, M.K., Plummer, W.D. Jr., Palmer, P.S. and Wright, P.F. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza a disease. Journal of Infectious Diseases 1994, 169, 68-76.
6. Barker, W.H. and Mullooly, J.P. Influenza vaccination of elderly persons. Reduction in pneumonia and influenza hospitalizations and deaths. JAMA 1980, 244, 2547-2549.
7. Foster, D.A., Talsma, A., Furumoto-Dawson, A., Ohmit, S.E., Margulies, J.R., Arden, N.H. and Monto A.S. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. American Journal of Epidemiology 1992, 136, 296-307.
8. Phair, J., Kauffman, C.A., Bjornson, A., Adams, L. and Linnemann, C. Jr. Failure to respond to influenza vaccine in the aged: correlation with B-cell number and function. Journal of Laboratory and Clinical Medicine 1978, 92, 822-828.
9. Feery, B., Evered, M.G. and Morrison, E.I. Different protection rates in various groups of volunteers given subunit influenza virus vaccine in 1976. Journal of Infectious Diseases 1979, 139, 237-241.
10. Palache, A.M., Beyer, W.E.P., Lüchters, G., Völker, R., Sprenger, M.J.W. and Masurel, N. Influenza vaccines: the effect of vaccine dose on antibody response in primed populations during the ongoing interpandemic period. A review of the literature. Vaccine 1993, 11, 892-908.
11. Barry, D.W., Mayner, R.E., Hochstein, H.D., Dunlap, R.C., Rastogi, S.C., Hannah, J.E., Blackburn, R.J., Sullivan, J.L. and Gerety, R.J. Comparative trial of influenza vaccines II. Adverse reactions in children and adults. American Journal of Epidemiology 1976, 104, 47-59.
12. Pickering, J.M., Smith, H. and Sweet, C. Influenza virus pyrogenicity: central role of structural orientation of virion components and involvement of viral lipid and glycoproteins. Journal of General Virology 1992, 73, 1345-1354.
13. 4 on purified influenza hemagglutinin in man. Journal of Immunology 1968, 100, 1139-1140.
14. Gerth, H.-J. and Mok-Hsu, Y.C. Reactogenicity and aerological response to polyvalent aqueous and aluminum hydroxide absorbed tween ether split fluid vaccine in young adults 1979. Infection 1981, 9, 85-90.
15. Mbawuike, I.N., Wyde, P.R. and Anderson, R.M. Enhancement of protective efficacy of inactivated influenza A virus vaccine in aged mice by IL-2 liposomes. Vaccine 1990, 8, 347-352.
16. Powers, D.C., Hanscome, P.J. and Pietrobon, P.J.F. In previously immunized elderly adults inactivated influenza A (H1N1) virus vaccines induce poor antibody responses that are not enhanced by liposome adjuvant. Vaccine 1995, 13, 1330-1335.
17. Gravenstein, S., Drinka, R., Duthie, E.H., Miller, B.A., Brown, C.S., Hensley, M., Circo, R., Langer, E. and Ershler, W.B. Efficacy of an influenza hemagglutinin-diphtheria toxoid conjugate vaccine in elderly nursing home subjects during an influenza outbreak. Journal of the American Geriatric Society 1994, 42, 245-251.
18. Tamizifar, H., Robinson, A., Jennings, R. and Potter, C. Immune response and protection against influenza A infection in mice immunized with subunit influenza A vaccine in combination with whole cell or acellular DTP vaccine. Vaccine 1995, 13, 1539-1546.
19. Sunquist, B., Lougren, K. and Morein, B. Influenza virus ISCOMS: antibody response in animals. Vaccine 1988, 6, 49-53.
20. Kaji, M., Kaji, Y., Kaji, M., Ohkuma, K., Honda, T., Oka, T., Mitsuo, S., Nakamura, S., Kurachi, K. and Sertoku, M. Phase I clinical tests of influenza MDP-virosome vaccine. Vaccine 1992, 10, 663-667.
21. Kreuter, J. and Liehl, E. Long term studies of micro-encapsulated and absorbed influenza vaccine nanoparticles. Journal of Pharmaceutical Science 1981, 70, 367-371.
22. Ott, G., Barchfeld, G.L., Chernoff, D., Radhakrishnan, R., van Hoogevest, P. and Van Nest, G.A. MF59. In: Vaccine Design: The Subunit and Adjuvant Approach (Eds Powell, M.F. and Newman, M.J.). Plenum Press, New York, 1995, pp. 277-296.
23. Van Nest, G.A., Steimer, K.S., Haigwood, N.L., Burke, R.L. and Ott, G. Advanced adjuvant formulations for use with recombinant subunit vaccines. Vaccines 92. Cold Spring Harbor Laboratory Press, Cold Spring Harbour, NY, 1992, pp. 57-62.
24. Burke, R.L. Current status of HSV vaccine development. In The Human Herpesviruses (Eds Roizman, B., Whitley, R.J. and Lopez, C.). Raven Press, New York, 1993, pp. 367-379.
25. Higgins, D.A., Carlson, J.R. and Van Nest, G. MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. Vaccine 1996, 14, 478-484.
26. Ott, G., Barchfeld, G.L. and Van Nest, G. Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine 1995, 13, 1557-1562.
27. Valensi, J.P.M., Carlson, J.R. and Van Nest, G.A. Systemic cytokine profiles in Balb/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. Journal of Immunology 1994, 153, 4029-4039.
28. Wang, J.B., Adler, S.P., Hempfling, S., Burke, R.L., Duliège, A.-M., Starr, S.E. and Plotkin, S.A. Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus. Journal of Infectious Diseases 1996, 1996, 387-392.
29. Choo, Q.-L., Kuo, G., Ralston, R., Weiner, A., Chien, D., Van Nest, G., Han, J., Berger, K., Thudium, K., Kuo, C., Kansopon, J., McFarland, J., Tabrizi, A., Ching, K., Moss, B., Cummins, L.B., Houghton, M. and Muchmore, E. Vaccination of chimpanzees against infection by the hepatitis C virus. Proceedings of the National Academy of Sciences of the United States of America 1994, 91, 1294-1298.
30. d mice. Scandinavian Journal of Immunology 1995, 42, 557-563.
31. Traquina, P., Morandi, M., Contorni, M. and Van Nest, G. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. Journal of Infectious Diseases 1996, 174, 1168-1175.
32. Langenberg, A.G.M., Burke, R.L., Adair, S.F., Sekulovich, R., Tigges, M., Dekker, C. and Corey, L. A recombinant glycoprotein vaccine for herpes simplex type 2: safety and immunogenicity. Annals of International Medicine 1995, 122, 889-898.
33. Martin, T., De Donato, S., Minutello, A., Lecchi, A.L., Adair, S., Pellegrini, V., Sekulovich, R. and Van Nest, G. Safety and immunogenicity of biocine adjuvanted influenza vaccine in elderly patients. 7th European Congress of Clinical Microbiology and Infectious Diseases (Vienna). Excerpta Medica, Confer Press, Amsterdam, Abstract 111, 1995.
34. Kahn, J.O., Sinangil, E., Baenziger, J., Murcar, N., Wynne, D., Coleman, R.L., Steimer, K.S., Dekker, C.L. and Chernoff, D. Clinical and immunologic responses to Human Immunodeficiency Virus (HIV) type I SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. Journal of Infectious Diseases 1994, 170, 1288-1291.
35. Monto, A.S., Ohmit, S.E., Margulies, J.R. and Talsma, A. Medical practice-based influenza surveillance: viral prevalence and assessment of morbidity. American Journal of Epidemiology 1995, 141, 502-506.